Who we are
The From Testing to Targeted Treatment Program (FT3), established in 2020, is a non-profit, multi-stakeholder global initiative. FT3 is bringing the right people together and building a neutral forum to reach the shared goal to make precision medicine an accessible reality for all patients who could benefit from it.
We believe that shared leadership and shared decision making, starting with the patient community, is critical to make sustainable change. We seek to foster balanced dialogue and practical solution building between individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.
A global multi-stakeholder precision medicine accelerator
Co-led by patients
Shared decision making and solution building across diverse stakeholder groups
Bringing together and building on existing learnings and good practices
Starting with testing and cancer
FT3 is a global accelerator of change, working together with diverse stakeholders to identify common gaps, scale good practices and defragment efforts in precision medicine. Our goal is to share and support local good practices and build a backbone of expertise and practical resources that are designed to be adapted to support patient organizations and other precision medicine champions on the ground.
Quotes from members
I believe that this is the first and only global coalition to address this issue by bringing patients, advocates, pharma and diagnostic companies, HCPs, payers, and regulators who will all work together to establish best practices to make personalized care accessible to all people.
Susan McClure
Genome Creative